Illumina (NASDAQ:ILMN) Shares Down 6% – Time to Sell?

Illumina, Inc. (NASDAQ:ILMN)’s share price dropped 6% on Tuesday. The company traded as low as $275.03 and last traded at $276.1260. Approximately 1,628,854 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 2,151,239 shares. The stock had previously closed at $293.69.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: RBC raised its price target to $310 from $230 and reaffirmed an “outperform” rating, citing improving fundamentals and potential upside from current levels. The upgrade helped push Illumina to a new one-year high. Royal Bank Of Canada Issues Positive Forecast for Illumina Stock Price
• Positive Sentiment: RBC also described Illumina’s clinical sequencing revenue as a potentially durable mid-teens growth business, strengthening the outlook for recurring demand from hospitals, laboratories and pharmaceutical customers. Illumina’s Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower
• Positive Sentiment: Investors are increasingly viewing Illumina’s sequencing platforms as potential infrastructure for artificial-intelligence applications, while analysts anticipate improved clinical sales and additional growth catalysts. The company’s higher 2026 guidance and September addition to the S&P 500 have provided further momentum. Illumina Shares Skyrocket, What You Need to Know
• Neutral Sentiment: The broader genomics sector also received attention after EpiSign and Geneyx announced a rare-disease analysis partnership incorporating PacBio sequencing data. The announcement supports industry-wide interest in genomic interpretation but has no direct financial impact on Illumina. EpiSign and Geneyx Announce Partnership
• Negative Sentiment: Valuation and insider activity remain risks. Illumina trades at roughly 52 times earnings, while reported insider transactions show substantial selling and no open-market purchases over the past six months. This could limit upside if growth expectations weaken.

Analyst Ratings Changes

ILMN has been the subject of several recent analyst reports. Evercore restated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Stifel Nicolaus upped their target price on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. TD Cowen lifted their price target on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research note on Friday, July 31st. Finally, Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Saturday. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $219.69.

Illumina Price Performance

The firm has a market capitalization of $41.86 billion, a PE ratio of 51.72, a price-to-earnings-growth ratio of 3.87 and a beta of 1.41. The stock’s 50 day simple moving average is $221.46 and its two-hundred day simple moving average is $177.17. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Activity

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at $2,685,684.96. The trade was a 6.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the transaction, the director directly owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. The trade was a 13.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ILMN. Baker Tilly Wealth Management LLC boosted its stake in shares of Illumina by 3.3% in the 3rd quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company’s stock valued at $355,000 after buying an additional 42 shares during the period. Argent Capital Management LLC purchased a new stake in shares of Illumina during the third quarter worth approximately $4,005,000. QRG Capital Management Inc. raised its holdings in Illumina by 8.1% in the second quarter. QRG Capital Management Inc. now owns 7,261 shares of the life sciences company’s stock valued at $1,277,000 after acquiring an additional 546 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its position in shares of Illumina by 18.6% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 6,935 shares of the life sciences company’s stock valued at $1,219,000 after purchasing an additional 1,090 shares during the last quarter. Finally, Tidal Investments LLC raised its holdings in shares of Illumina by 10.3% in the 2nd quarter. Tidal Investments LLC now owns 93,728 shares of the life sciences company’s stock valued at $16,480,000 after purchasing an additional 8,726 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.